A citation-based method for searching scientific literature

Sarah A Laurent, Franziska S Hoffmann, Peer-Hendrik Kuhn, Qingyu Cheng, Yuanyuan Chu, Marc Schmidt-Supprian, Stefanie M Hauck, Elisabeth Schuh, Markus Krumbholz, Heike Rübsamen, Johanna Wanngren, Mohsen Khademi, Tomas Olsson, Tobias Alexander, Falk Hiepe, Hans-Walter Pfister, Frank Weber, Dieter Jenne, Hartmut Wekerle, Reinhard Hohlfeld, Stefan F Lichtenthaler, Edgar Meinl. Nat Commun 2015
Times Cited: 167







List of co-cited articles
1301 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Noopur Raje, Jesus Berdeja, Yi Lin, David Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V Maus, Ashley Turka,[...]. N Engl J Med 2019
649
47

BCMA is essential for the survival of long-lived bone marrow plasma cells.
Brian P O'Connor, Vanitha S Raman, Loren D Erickson, W James Cook, Lehn K Weaver, Cory Ahonen, Ling-Li Lin, George T Mantchev, Richard J Bram, Randolph J Noelle. J Exp Med 2004
692
43

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Adam D Cohen, Alfred L Garfall, Edward A Stadtmauer, J Joseph Melenhorst, Simon F Lacey, Eric Lancaster, Dan T Vogl, Brendan M Weiss, Karen Dengel, Annemarie Nelson,[...]. J Clin Invest 2019
304
42

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Jennifer N Brudno, Irina Maric, Steven D Hartman, Jeremy J Rose, Michael Wang, Norris Lam, Maryalice Stetler-Stevenson, Dalia Salem, Constance Yuan, Steven Pavletic,[...]. J Clin Oncol 2018
369
41

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Robert O Carpenter, Moses O Evbuomwan, Stefania Pittaluga, Jeremy J Rose, Mark Raffeld, Shicheng Yang, Ronald E Gress, Frances T Hakim, James N Kochenderfer. Clin Cancer Res 2013
372
41

γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
Margot J Pont, Tyler Hill, Gabriel O Cole, Joe J Abbott, Jessica Kelliher, Alexander I Salter, Michael Hudecek, Melissa L Comstock, Anusha Rajan, Bharvin K R Patel,[...]. Blood 2019
112
38

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
Wan-Hong Zhao, Jie Liu, Bai-Yan Wang, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei,[...]. J Hematol Oncol 2018
241
37

Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.
Eric Sanchez, Mingjie Li, Alex Kitto, Jennifer Li, Cathy S Wang, Dylan T Kirk, Ori Yellin, Cydney M Nichols, Marissa P Dreyer, Cameryn P Ahles,[...]. Br J Haematol 2012
141
34

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.
Yu-Tzu Tai, Patrick A Mayes, Chirag Acharya, Mike Y Zhong, Michele Cea, Antonia Cagnetta, Jenny Craigen, John Yates, Louise Gliddon, William Fieles,[...]. Blood 2014
261
29

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.
Max S Topp, Johannes Duell, Gerhard Zugmaier, Michel Attal, Philippe Moreau, Christian Langer, Jan Krönke, Thierry Facon, Alexey V Salnikov, Robin Lesley,[...]. J Clin Oncol 2020
138
29

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
Jie Xu, Li-Juan Chen, Shuang-Shuang Yang, Yan Sun, Wen Wu, Yuan-Fang Liu, Ji Xu, Yan Zhuang, Wu Zhang, Xiang-Qin Weng,[...]. Proc Natl Acad Sci U S A 2019
166
28


APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.
Yu-Tzu Tai, Chirag Acharya, Gang An, Michele Moschetta, Mike Y Zhong, Xiaoyan Feng, Michele Cea, Antonia Cagnetta, Kenneth Wen, Hans van Eenennaam,[...]. Blood 2016
162
27

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.
Anne J Novak, Jaime R Darce, Bonnie K Arendt, Brandon Harder, Kathy Henderson, Wayne Kindsvogel, Jane A Gross, Philip R Greipp, Diane F Jelinek. Blood 2004
356
26

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.
Syed Abbas Ali, Victoria Shi, Irina Maric, Michael Wang, David F Stroncek, Jeremy J Rose, Jennifer N Brudno, Maryalice Stetler-Stevenson, Steven A Feldman, Brenna G Hansen,[...]. Blood 2016
463
26

Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M Voorhees, Brandi Reeves, Edward N Libby, Paul G Richardson, Larry D Anderson, Heather J Sutherland, Kwee Yong,[...]. Lancet Oncol 2018
135
26

Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Anja Seckinger, Jose Antonio Delgado, Samuel Moser, Laura Moreno, Brigitte Neuber, Anna Grab, Susanne Lipp, Juana Merino, Felipe Prosper, Martina Emde,[...]. Cancer Cell 2017
176
25

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.
Michael Ghermezi, Mingjie Li, Suzie Vardanyan, Nika Manik Harutyunyan, Jillian Gottlieb, Ariana Berenson, Tanya M Spektor, Claudia Andreu-Vieyra, Sophia Petraki, Eric Sanchez,[...]. Haematologica 2017
72
31

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Sagar Lonial, Meletios Dimopoulos, Antonio Palumbo, Darrell White, Sebastian Grosicki, Ivan Spicka, Adam Walter-Croneck, Philippe Moreau, Maria-Victoria Mateos, Hila Magen,[...]. N Engl J Med 2015
890
22

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Sagar Lonial, Hans C Lee, Ashraf Badros, Suzanne Trudel, Ajay K Nooka, Ajai Chari, Al-Ola Abdallah, Natalie Callander, Nikoletta Lendvai, Douglas Sborov,[...]. Lancet Oncol 2020
266
22

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Eric L Smith, Kim Harrington, Mette Staehr, Reed Masakayan, Jon Jones, Thomas J Long, Khong Y Ng, Majid Ghoddusi, Terence J Purdon, Xiuyan Wang,[...]. Sci Transl Med 2019
113
21

Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Kevin M Friedman, Tracy E Garrett, John W Evans, Holly M Horton, Howard J Latimer, Stacie L Seidel, Christopher J Horvath, Richard A Morgan. Hum Gene Ther 2018
96
21

Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.
Eric Sanchez, Abigail Gillespie, George Tang, Morgan Ferros, Nika Manik Harutyunyan, Suzie Vardanyan, Jillian Gottlieb, Mingjie Li, Cathy S Wang, Haiming Chen,[...]. Clin Cancer Res 2016
56
35

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Nina Shah, Ajai Chari, Emma Scott, Khalid Mezzi, Saad Z Usmani. Leukemia 2020
110
20

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Shannon L Maude, Theodore W Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, Michael R Verneris, Heather E Stefanski, Gary D Myers,[...]. N Engl J Med 2018
19

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin,[...]. N Engl J Med 2017
19

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.
Alfred L Garfall, Marcela V Maus, Wei-Ting Hwang, Simon F Lacey, Yolanda D Mahnke, J Joseph Melenhorst, Zhaohui Zheng, Dan T Vogl, Adam D Cohen, Brendan M Weiss,[...]. N Engl J Med 2015
399
19

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.
Jérôme Moreaux, Eric Legouffe, Eric Jourdan, Philippe Quittet, Thierry Rème, Cécile Lugagne, Philippe Moine, Jean-François Rossi, Bernard Klein, Karin Tarte. Blood 2004
393
19


An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.
Lydia Lee, Benjamin Draper, Neil Chaplin, Brian Philip, Melody Chin, Daria Galas-Filipowicz, Shimobi Onuoha, Simon Thomas, Vania Baldan, Reyisa Bughda,[...]. Blood 2018
91
18

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
S Hipp, Y-T Tai, D Blanset, P Deegen, J Wahl, O Thomas, B Rattel, P J Adam, K C Anderson, M Friedrich. Leukemia 2017
127
17

Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study.
Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M Voorhees, Brandi Reeves, Edward N Libby, Paul G Richardson, Axel Hoos, Ira Gupta, Veronique Bragulat,[...]. Blood Cancer J 2019
120
17

The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily.
C Madry, Y Laabi, I Callebaut, J Roussel, A Hatzoglou, M Le Coniat, J P Mornon, R Berger, A Tsapis. Int Immunol 1998
105
16

Multiple myeloma.
Antonio Palumbo, Kenneth Anderson. N Engl J Med 2011
15

Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
Lydia Lee, Danton Bounds, Jennifer Paterson, Gaelle Herledan, Katherine Sully, Laura M Seestaller-Wehr, William E Fieles, James Tunstead, Lee McCahon, Fiona M Germaschewski,[...]. Br J Haematol 2016
78
19

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Nikhil C Munshi, Larry D Anderson, Nina Shah, Deepu Madduri, Jesús Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, David Siegel, Albert Oriol,[...]. N Engl J Med 2021
266
15

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Sattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, William Wierda, Cristina Gutierrez, Frederick L Locke, Krishna V Komanduri, Yi Lin, Nitin Jain, Naval Daver,[...]. Nat Rev Clin Oncol 2018
14

A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Zhiling Yan, Jiang Cao, Hai Cheng, Jianlin Qiao, Huanxin Zhang, Ying Wang, Ming Shi, Jianping Lan, Xiaoming Fei, Lai Jin,[...]. Lancet Haematol 2019
136
14

Targeting B-cell maturation antigen in multiple myeloma.
Yu-Tzu Tai, Kenneth C Anderson. Immunotherapy 2015
106
14

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Antonio Palumbo, Asher Chanan-Khan, Katja Weisel, Ajay K Nooka, Tamas Masszi, Meral Beksac, Ivan Spicka, Vania Hungria, Markus Munder, Maria V Mateos,[...]. N Engl J Med 2016
896
14

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Daniel W Lee, Bianca D Santomasso, Frederick L Locke, Armin Ghobadi, Cameron J Turtle, Jennifer N Brudno, Marcela V Maus, Jae H Park, Elena Mead, Steven Pavletic,[...]. Biol Blood Marrow Transplant 2019
831
13

Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
Xiuli Wang, Miriam Walter, Ryan Urak, Lihong Weng, Christian Huynh, Laura Lim, ChingLam W Wong, Wen-Chung Chang, Sandra H Thomas, James F Sanchez,[...]. Clin Cancer Res 2018
85
15

Chimeric antigen receptor T-cell therapies for multiple myeloma.
Lekha Mikkilineni, James N Kochenderfer. Blood 2017
127
13

Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells.
Krista Kinneer, Matt Flynn, Suneetha B Thomas, John Meekin, Reena Varkey, Xiaodong Xiao, Haihong Zhong, Shannon Breen, Paul G Hynes, Ryan Fleming,[...]. Leukemia 2019
39
33

BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.
Danielle T Avery, Susan L Kalled, Julia I Ellyard, Christine Ambrose, Sarah A Bixler, Marilyn Thien, Robert Brink, Fabienne Mackay, Philip D Hodgkin, Stuart G Tangye. J Clin Invest 2003
360
13

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Eric D Hsi, Roxanne Steinle, Balaji Balasa, Susann Szmania, Aparna Draksharapu, Benny P Shum, Mahrukh Huseni, David Powers, Amulya Nanisetti, Yin Zhang,[...]. Clin Cancer Res 2008
386
13

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Ujjawal H Gandhi, Robert F Cornell, Arjun Lakshman, Zhubin J Gahvari, Elizabeth McGehee, Megan H Jagosky, Ridhi Gupta, William Varnado, Mark A Fiala, Saurabh Chhabra,[...]. Leukemia 2019
182
13

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin,[...]. N Engl J Med 2019
12

The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed.
Y Laabi, M P Gras, J C Brouet, R Berger, C J Larsen, A Tsapis. Nucleic Acids Res 1994
157
12

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Yu-Tzu Tai, Myles Dillon, Weihua Song, Merav Leiba, Xian-Feng Li, Peter Burger, Alfred I Lee, Klaus Podar, Teru Hideshima, Audie G Rice,[...]. Blood 2008
355
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.